Uncategorized

GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting

by Business Wire • 2021/11/12 • 0 Comments

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that clinical data of LUMEVOQ® and GS030 gene therapies will be presented at the 125th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, Louisiana (November 12-15, 2021). Re

Full Story →

← EvoqTM Technologies Achieves Breakthrough With Its Smartphone-Based System for Early Detection and Diagnosis of Diseases

Global Optical Coherence Tomography Market (2021 to 2029) – by Technology Type, Application Type and Geography – ResearchAndMarkets.com →

Post navigation